Funding

FinnGen study is funded by Business Finland and the pharmaceutical industry partners. The funding allocated for the entire six years (2017-2023) is approximately 92 M €.

The graph belows shows the FinnGen expenditure distribution. The data is based on December 2022 situation / budget forecast. 38% of the funding is used to cover costs related to biobank sample collection and handling. The next largest items of expenditure are data processing & analyses activities (19% of the budget, mainly personnel costs) and genotyping with ThermoFisher's array (12% of the budget). In addition, significant investments to IT and data security have been made (11% of the budget). Additional research data category (13%) includes costs related to new research activities launched during FinnGen2, such as collecting clinical data for selected disease areas, a questionnaire pilot, producing molecular profiling data to study the function of selected interesting genetic variants and a sub-study focusing on Alzheimer's disease.

Graph showing the expenditure distribution of FinnGen. The largest budget items are listed in the text. In addition, the graph contains the following items: Management, coordination and outreach (6%) and Meetings and travel (1%).

The total budget exceeds 92 M €. Approximately 20 M € comes from Business Finland and the rest from thirteen international pharmaceutical industry partners: AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene/Bristol-Myers Scibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer and Sanofi.

FinnGen in brief

FinnGen is a large public-private partnership aiming to collect and analyse genome and health data from 500,000 Finnish biobank participants. FinnGen aims on one hand to provide novel medically and therapeutically relevant insights but also construct a world-class resource that can be applied for future studies.

FinnGen is one of the very first personalized medicine projects at this scale and the public-private collaborative nature of the project is exceptional compared to many ongoing studies. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks, FINBB and international pharmaceutical companies and hundreds of thousands of Finns. Because collaboration is the key to achieving breakthroughs in disease prevention, diagnosis, and treatment, we welcome everyone on this journey into our shared heritage.